Skip to content

Telemedicine Evaluation for Stem Cell Transplant Patients

Pilot Trial of Telemedicine Evaluation for Stem Cell Transplant Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01324427
Enrollment
43
Registered
2011-03-29
Start date
2011-03-31
Completion date
2020-08-31
Last updated
2020-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stem Cell Transplant Patients

Keywords

Telemedicine, Virtual Medical Visit, Quality of Life, 11-022

Brief summary

Telemedicine is a new area of health care where medical information is transferred through audiovisual media, such as a computer or a video camera, for the purpose of remote doctor's visits or examinations. This new area of health care is important to test because it can potentially provide real-time interactions between the patient and their health care team, including phone conversations, online communication, and/or home visits. Many activities such as a history review or physical examination can be conducted virtually as compared to the traditional face-to face visits. The purpose of this study is to determine patient and health care team acceptance of a virtual medical visit as a substitute for a face to face visit for patients either preparing to receive a stem cell transplant or previously received a stem cell transplant.

Interventions

BEHAVIORALvirtual medical visit

At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits.

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* Patients who underwent or are planning to undergo a hematopoietic progenitor cell transplantation for any disease. * Participants must be able to read and understand English\* * Age over 18 years of age since this pilot trial is only being performed in the Adult BMT Service Non-English speaking patients have been excluded in this pilot study because we do not have the support for translation services at this time. Additionally, the telemedicine instruments being used are not yet validated across all languages. Potential patients will be identified according to their medical condition, type and complexity of stem cell transplant procedure performed, and distance from MSKCC. The patients should: 1. minimal comorbidities, 2. be less than 75 years of age. These characteristics have been associated with good understanding and acceptance of telemedicine in other pilot trials. These characteristics will be assessed by the clinician. Please note: Patients on other therapeutic protocols will be eligible for this protocol as well.

Exclusion criteria

* Medically unstable patient as deemed by the treating team.

Design outcomes

Primary

MeasureTime frameDescription
Determine patient & physician acceptance of a virtual medical visit as a substitute for a face to face in pts in different settings. This is assessed by analyzing answers to questions 7 & 8 of the Patient Satisfaction Survey. [Question #7: I would2 yearsQuestion #8: Overall, I was very satisfied with today's telemedicine session.\]Physician acceptance will be analyzed looking at the answers to question 19 of the Physician/Nurse survey in which the physician or nurse investigator relates the quality of the telemedicine visit. \[Question #19: How would you rate the quality of the Telehealth visit to assess the patient compared to an in-person office visit?\]

Secondary

MeasureTime frameDescription
Confirm that current telemedicine technology a comprehensive stem cell transplant clinical evaluation can be performed.2 yearsQuestions 1-12 of the healthcare provider survey will assess the quality of the information &assessment collected through the virtual medical visit.
Evaluate the feasibility of telemedicine facilitated handoffs between the inpatient and the outpatient service at the time of discharge from the inpatient service and at the time of discharge from the transplant center are feasible and useful.2 yearsThe instrument used to analyze the feasibility and utility of the handoff instrument is Provider Satisfaction Survey with Handoff Instrument Survey for Feedback on Handoff Instrument. We will collate these responses to determine whether the handoff instrument was found to be useful and what elements should be modified, removed or added.
Describe the logistic characteristics of a virtual medical visit performed using telemedicine such as visit times, connection quality, and quality of the clinical information obtained.2 yearsThe time from the first attempt to connect until the time to disconnect will be captured for all encounters as well as the time from the beginning to end of the virtual medical visit. We expect that the virtual medical visit should take on average 20 minutes from attempt to connect to disconnect.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026